Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.

NCT01767155 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.

NCT NCT01767155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01767155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Lead sponsor
AEterna Zentaris
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2013
Completion date
January 30, 2017
Enrollment
511 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer